Abstract 1334P
Background
SMARCA4 deficient (SMARCA4d) non-small cell lung cancer (NSCLC) has a poor prognosis. The activity of first line immune-checkpoint blockers (ICB) or chemo-ICB and the potential impact of co-mutations is scarcely explored in patients with SMARCA4d NSCLC.
Methods
This is a monocentric, retrospective study evaluating patients with advanced NSCLC, screened for SMARCA4 alterations and treated with first line chemo-ICB or ICB alone. SMARCA4d was defined as loss of BRG1 in immunohistochemistry or the presence of deleterious SMARCA4 in liquid or tissue biopsies assessed by next-generation sequencing. Progression-free survival (PFS), overall survival (OS) and the impact of co-mutations (STK11, KEAP1) were compared between patients with or without SMARCA4d.
Results
A total of 128 patients were included: 36 with SMARCA4d (12 in IHC, 31 in NGS, 7 both) and 92 without SMARCA4d (control group). Patients with SMARCA4d had a median age of 57 years, were male in 64% cases and smokers in 94% cases, similar to the control group. Histology type was adenocarcinoma in 53% versus 82% (p<0.001) in control, with more cases of undifferentiated or large cell neuroendocrine carcinoma in the SMARCA4d group. TMB value was 13 vs 5 mut/Mb (p<0.001), median PD-L1 expression was 0 vs 5% (p=0.3) in SMARCA4d versus control, with no differences in immune blood counts. STK11 and KEAP1 mutations were frequently co-mutated with SMARCA4d (53% vs 26%, p= 0,01; 37% vs 13%, p= 0,01, respectively. The median PFS under ICB+/- chemotherapy was 4.0 months (CI 95% 2.87- 7.7) vs 7.37 months (CI 95% 6.53-11.3) (p= 0.005) in SMARCA4d versus control, and the median OS was 9.3 months (CI 95% 7.0 – NR) vs 27.6 months (CI 95% 27.3 - NA) (p< 0.0001), respectively. In patients with STK11/KEAP1 mutations, median OS was 7 months (95% CI 5-NR) versus 13.3 months (95% CI 10.5-35.8) (p=0.19) in SMARCA4 and control, respectively.
Conclusions
SMARCA4d seems to negatively impact survival outcomes and the efficacy of ICB, despite high TMB. Novel treatments are rapidly needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Remon Masip: Financial Interests, Personal, Invited Speaker: Roche, MSD, Boehringer Ingelheim; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Personal, Advisory Board: AstraZeneca, Ose Immunotherapeutics, BMS, Janssen, Takeda, Sanofi; Financial Interests, Institutional, Invited Speaker: Merck Portugal; Non-Financial Interests, Principal Investigator, PI of PECATI trial in Thymic malignancies endorsed by a grant by MSD: MSD; Non-Financial Interests, Other, Co-PI of APPLE trial (EORTC-1525): AstraZeneca; Non-Financial Interests, Member, Secretary of the Lung Cancer Group at the EORTC: EORTC. A. Levy: Financial Interests, Institutional, Invited Speaker: Pharma Mar; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Institutional, Coordinating PI: BeiGene. F. Barlesi: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda, AbbVie, Acea, Amgen, Eisai, Ignyta; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann-La Roche Ltd., Innate Pharma, Mirati. D. Planchard: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Samsung, Celgene, AbbVie, Daiichi Sankyo, Janssen, Seagen, Gilead, Pierre Fabre; Financial Interests, Personal, Invited Speaker: AstraZeneca, Novartis, Pfizer, priME Oncology, Peer CME, Samsung, AbbVie, Janssen; Non-Financial Interests, Principal Investigator, Institutional financial interests: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Daiichi Sankyo, Sanofi-Aventis, Pierre Fabre; Non-Financial Interests, Principal Investigator: AbbVie, Sanofi, Janssen. B. Besse: Financial Interests, Institutional, Funding: 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Onxeo, Ose Immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals; Financial Interests, Institutional, Research Grant: Genzyme Corporation, Chugai Pharmaceutical, Eisai, Inivata, Ipsen, Turning Point Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1068P - Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in melanoma and lung cancer models
Presenter: Salvatore Cortellino
Session: Poster session 19
1070P - Patterns of adverse reactions for immune checkpoint inhibitors in cancer patients with central nervous system metastases
Presenter: Tianqi Gu
Session: Poster session 19
1071P - Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database
Presenter: Zimu Li
Session: Poster session 19
1072P - DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models
Presenter: Sina Fellermeier-Kopf
Session: Poster session 19
1073P - Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models
Presenter: Ilya Tsimafeyeu
Session: Poster session 19
1074TiP - A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Presenter: Martin Gutierrez
Session: Poster session 19
1075TiP - A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
Presenter: Ecaterina Dumbrava
Session: Poster session 19
1076TiP - First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
Presenter: Sunil Babu
Session: Poster session 19
1077TiP - TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Presenter: Harshabad Singh
Session: Poster session 19